Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Tuesday 01 June, 2021

Omega Diagnostics Gp

Positive data for COVID-19 antigen test

RNS Number : 3095A
Omega Diagnostics Group PLC
01 June 2021


("Omega" or the "Company" or the "Group")


Positive study data for Mologic COVID-19 lateral flow antigen test

Test shows high diagnostic accuracy ( specificity and sensitivity) exceeding WHO targets


Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of a manuscript entitled: "Accuracy of the Mologic COVID-19 rapid antigen test: a prospective multi-centre analytical and clinical evaluation" which provides positive study data relating to Mologic Ltd's ('Mologic') lateral flow antigen test for COVID-19.


The study concludes that the Mologic test, which has been commercialized by Omega as the VISITECT® COVID-19 Antigen test , has fulfilled the WHO target diagnostic accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct<20 and Ct<25).


The VISITECT® COVID-19 Antigen test provides healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs in 10 minutes.  


The Mologic COVID-19 rapid test was evaluated in a prospective multicentre study across UK sites, where a total of 347 participants were enrolled. The Diagnostic accuracy and clinical performance of the test were investigated by comparing to gold standard RT-PCR results from individuals with and without COVID-19 symptoms attending secondary care facilities in Merseyside, ambulance services in Yorkshire, and drive-through testing facilities in Northumberland, UK.


With data stratified by RT-PCR cycle threshold (Ct), sensitivity was shown to be high in individuals with highest viral loads (i.e. most likely to be highly contagious): 93.2% of samples with a Ct less than 25 and 98.4% of samples with a Ct less than 20. Overall sensitivity (including all cycle thresholds, so individuals with low viral loads as well) and specificity compared to the reference SARS-CoV-2 RT-PCR was 85.0% and 97.8% respectively.


The study also concluded that the Mologic test replicated diagnostic accuracy in a variety of settings important for COVID-19 control (hospitals, ambulatory services, and drive-through centres) and on self-collected swab specimens. The manuscript can be viewed here:


Colin King, CEO of Omega, commented:  "This is great news for the Mologic test, which we are now producing under our VISITECT ® brand. It is significant that the test has been shown to have high diagnostic accuracy, but also that this performance is replicated across multiple different settings, different demographics, and on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests."





Omega Diagnostics Group PLC

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t